Astellas Gains Ex-Asia Rights to Tivozanib from AVEO in Potential US$1.4 B Deal
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 3 (Table of Contents)
Published: 7 Mar-2011
DOI: 10.3833/pdr.v2011.i3.1442 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Astellas has emphasised its strategic focus on oncology by signing a development and commercialisation agreement outside of Asia for tivozanib, AVEO Pharmaceuticals’ Phase III drug candidate whose lead indication is advanced renal cell carcinoma...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS